<SEC-DOCUMENT>0001193125-19-248388.txt : 20190918
<SEC-HEADER>0001193125-19-248388.hdr.sgml : 20190918
<ACCEPTANCE-DATETIME>20190918170710
ACCESSION NUMBER:		0001193125-19-248388
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20190917
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190918
DATE AS OF CHANGE:		20190918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		191100363

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d806643d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20190917" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2019-09-17_to_2019-09-17">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2019-09-17_to_2019-09-17">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2019-09-17_to_2019-09-17">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20190917.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2019-09-17_to_2019-09-17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-17</xbrli:startDate> <xbrli:endDate>2019-09-17</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">WASHINGTON, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2019-09-17_to_2019-09-17">8-K</ix:nonNumeric> </span></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section&#160;13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt:datemonthdayyearen">September&#160;17, 2019</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ACADIA Pharmaceuticals Inc.</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2019-09-17_to_2019-09-17">000-50768</ix:nonNumeric> </span></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2019-09-17_to_2019-09-17">06-1376651</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction of</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">incorporation or organization)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="font-size:1pt;">
<td colspan="3" style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2019-09-17_to_2019-09-17">3611 Valley Centre Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2019-09-17_to_2019-09-17">Suite 300</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2019-09-17_to_2019-09-17">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td>&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2019-09-17_to_2019-09-17">92130</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td>&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2019-09-17_to_2019-09-17">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2019-09-17_to_2019-09-17">558-2871</ix:nonNumeric> </span></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">N/A</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former name or former address, if changed since last report.)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form <span style="white-space:nowrap">8-K): </span></p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b)) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;text-align:left;">&#160;</td>
<td style="width:4%;vertical-align:top;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c)) </span></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-09-17_to_2019-09-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-09-17_to_2019-09-17">ACAD</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#32;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167;&#32;<span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2019-09-17_to_2019-09-17" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:0"></p></div>

<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;8.01&#32;</td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other Events.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On September&#160;17, 2019, ACADIA Pharmaceuticals Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (the &#8220;Underwriters&#8221;), relating to the sale and issuance of 6,250,000 shares of the Company&#8217;s common stock. The price to the public in this offering was $40.00 per share. The net proceeds to the Company from this offering are expected to be approximately $235.8&#160;million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is scheduled to close on or about September&#160;20, 2019, subject to customary closing conditions. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to 937,500 additional shares of common stock. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The offering was made pursuant to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement No.<span style="white-space:nowrap">&#160;333-228546), </span>&#32;which became automatically effective upon filing with the Securities and Exchange Commission on November&#160;26, 2018, and a prospectus supplement thereunder. The Underwriting Agreement is filed as Exhibit 1.1 to this report and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto. </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">On September&#160;17, 2019, the Company issued a press release announcing that it had commenced the offering and a press release announcing that it had priced the offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000">Number </p> </td>
<td style="white-space:nowrap;vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt"> <span style="text-decoration:underline">Description</span> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;1.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d806643dex11.htm">Underwriting Agreement, dated September&#160;17, 2019 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;5.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d806643dex51.htm">Opinion of Cooley LLP </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">23.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d806643dex51.htm">Consent of Cooley LLP (included in Exhibit 5.1) </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d806643dex991.htm">Press Release, dated September&#160;17, 2019 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.2 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d806643dex992.htm">Press Release, dated September&#160;17, 2019 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104</p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p> </td> </tr> </table> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Forward-Looking Statements </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Certain statements in this report that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the closing of the transaction contemplated by the Underwriting Agreement and the expected net proceeds to the Company from the offering. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those stated in any such statements due to various factors, including uncertainties related to satisfaction of customary closing conditions, some of which are discussed in the section captioned &#8220;Risk Factors&#8221; in the Company&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2018 as well as the Company&#8217;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. </p> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:45%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:4%;"></td>
<td style="width:1%;"></td>
<td style="width:44%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: September&#160;18, 2019 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">ACADIA Pharmaceuticals Inc. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Name: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Austin D. Kim </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Title: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Executive Vice President, General Counsel&#160;&#038; Secretary </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d806643dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><I></I><B><I>Execution Version</I></B><I></I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA
PHARMACEUTICALS INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;17, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">as
Representatives of the several Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10036 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">J.P. Morgan Securities LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B> ACADIA Pharmaceuticals Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the
several underwriters named on <U>Schedule A</U> hereto (the &#147;<B>Underwriters</B>&#148;) an aggregate of 6,250,000 shares of its common stock, par value $0.0001 per share (the &#147;<B>Shares</B>&#148;). The 6,250,000 Shares to be sold by the
Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an option to purchase up to an additional 937,500 Shares, as provided in Section&nbsp;2. The additional 937,500 Shares to be sold by the
Company pursuant to such option are called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; BofA
Securities, Inc. (&#147;<B>BofAS</B>&#148;) and J.P. Morgan Securities LLC (&#147;<B>J.P. Morgan</B>&#148;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection
with the offering and sale of the Offered Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) a shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-228546,</FONT> including a base prospectus (the &#147;<B>Base
Prospectus</B>&#148;) to be used in connection with the public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became
effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference
therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the
Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of any such Rule
462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated September&nbsp;17, 2019 describing the Offered
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares and the offering thereof (the &#147;<B>Preliminary Prospectus Supplement</B>&#148;), together with the Base Prospectus, is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the
Preliminary Prospectus and any other prospectus supplement to the Base Prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the
Base Prospectus, is called a &#147;<B>preliminary prospectus</B>.&#148; As used herein, the term &#147;<B>Prospectus</B>&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Shares and the offering
thereof (the &#147;<B>Final Prospectus Supplement</B>&#148;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares<B> </B>or in the form first made available to the Underwriters by the
Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base
Prospectus components of such prospectus. As used herein, &#147;<B>Applicable Time</B>&#148; is 6:30 p.m. (New York City time) on September&nbsp;17, 2019. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule
405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in
<U>Schedule B</U> hereto and the pricing information set forth on <U>Schedule C</U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the
Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein.
All references in this Agreement to financial statements and schedules and other information which are &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b)
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial
statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus,
the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of
Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange
Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement
to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy
thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in
connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(o) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company
has only one subsidiary, then all references herein to &#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B>Representations and Warranties </B><B>of the Company. </B>The Company hereby represents, warrants and
covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Compliance with Registration Requirements</I></B><B>.</B> The Registration
Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the
effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the Company&#146;s knowledge, are contemplated or threatened by the Commission. At the time the Company&#146;s
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 (the &#147;<B>Annual Report</B>&#148;) was filed with the Commission, or, if later, at the time the Registration Statement was originally
filed with the Commission, as well as at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Securities Act) made any offer relating to the Offered Shares in reliance on the
exemption of Rule 163 under the Securities Act, the Company was a &#147;well known seasoned issuer&#148; as defined in Rule 405 under the Securities Act. The Registration Statement is an &#147;automatic shelf registration statement,&#148; as defined
in Rule 405 under the Securities Act, and became effective on November&nbsp;26, 2018. The Company has not received from the Commission any notice pursuant to Rule 401(g)(2) under the Securities Act objecting to the Company&#146;s use of the
automatic shelf registration form. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission,
or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Disclosure</I></B><B>.</B> Each preliminary prospectus and the Prospectus when filed complied in all material respects with
the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act) to the copy thereof delivered to the
Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material
respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable
Time, the Time of Sale Prospectus (including any preliminary prospectus wrapper) did not, and at the First Closing Date (as defined in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper), as of its
date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective
amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the
Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time
of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses; Road Show</I></B><B>.</B> As of the determination date referenced in Rule&nbsp;164(h) under the
Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing
prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the Company
has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or
retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any
information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded or modified. Except for the free writing prospectuses, if any,
identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing
prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Distribution of Offering Material by the
Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the several Underwriters in Section&nbsp;2, and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares, the
Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing
prospectus reviewed and consented to by the Representatives, or the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by, and is a valid
and binding agreement of, the Company, enforceable against the Company in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Authorization of the Offered Shares</I></B><B>.</B> The Offered Shares have been duly authorized for issuance and sale
pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights,
rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares, except for such rights as have been validly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>No Applicable Registration or Other Similar Rights</I></B><B>.</B> There are no persons with registration or other similar
rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>No Material Adverse Change</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development
that could be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects<B>,</B> whether or not arising from transactions in the
ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries, considered as one
entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether
or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its subsidiaries, considered as one entity, or has entered into any material transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in
the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid
to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Independent Accountants</I></B><B>.</B> Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the
financial statements (which term as used in this Agreement includes the related notes thereto) and supporting schedules filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an
independent registered public accounting firm as required by the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable requirements relating to the
qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose
registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Financial
Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the consolidated financial position of the
Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the periods specified. The supporting schedules included in the Registration Statement present fairly
in all material respects the information required to be stated therein. Such financial statements and supporting schedules have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a
consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be
included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. To the Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to
comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a
part of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
<B><I>Company</I></B><B><I>&#146;</I></B><B><I>s Accounting System</I></B><B>.</B> The Company and each of its subsidiaries make and keep books and records that are accurate in all material respects and maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal
Control Over Financial Reporting</I></B><B>.</B> The Company has established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT>
under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial
officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of
the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no
significant deficiencies or material weakness in the Company&#146;s internal control over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) (whether or not remediated) and no change in
the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its
internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company has been duly incorporated and is validly existing
as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the
Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of California and each
other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to qualify would not result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Subsidiaries</I></B><B>.</B> Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined
in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction
of its incorporation or organization, except to the extent that the failure to be in good standing would not result, singularly or in the aggregate, in a Material Adverse Change, and has the power and authority (corporate or other) to own, lease and
operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited
liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the
failure to qualify would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are
fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly,
any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21.1 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, or
subsidiaries that would not, individually or in the aggregate, be a significant subsidiary as defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The authorized, issued and outstanding capital stock of the
Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Capitalization&#148; (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise
of outstanding options or warrants, in each case described in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the
Time of Sale Prospectus. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, all of the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and
nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or
purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for,
any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&#146;s stock option, stock bonus and other stock
plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly presents in all material respects the information required to be
shown with respect to such plans, arrangements, options and rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Stock Exchange Listing</I></B><B>.</B> The Shares
are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and are listed on The Nasdaq Global Select Market (the &#147;<B>Nasdaq</B>&#148;), and the Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Shares under the Exchange Act or delisting the Shares from the Nasdaq, nor has the Company received any notification that the Commission or the Nasdaq is contemplating terminating such registration or listing. To
the Company&#146;s knowledge, it is in compliance with all applicable listing requirements of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I><FONT
STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
(&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument
or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject
(each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or other), earnings, business,
properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, considered as one entity (a &#147;<B>Material Adverse Effect</B>&#148;). The Company&#146;s execution, delivery and performance of this Agreement, and
consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, including the issuance and sale of the Offered Shares, (i)&nbsp;have been duly authorized by all necessary
corporate action and will not result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, of the
Company or any subsidiary, (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any
property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative
or court decree applicable to the Company or any of its subsidiaries, except for such conflicts, breaches or violations specified in subsection (ii)&nbsp;and (iii) above that would not reasonably be expected to result in a Material Adverse Change.
No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and
consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities
Act and such as may be required under applicable state securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or blue sky laws or the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;). As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition
which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Compliance with
Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>No Material Actions or Proceedings</I></B><B>.</B> Except as disclosed in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting
the Company or any of its subsidiaries, that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions contemplated by this Agreement or
the performance by the Company of its obligations hereunder and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the
subject, including ordinary routine litigation incidental to the business, if determined adversely to the Company, would not be expected to have a Material Adverse Effect. No labor dispute with the employees of the Company or any of its
subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent, except as would not reasonably be expected to have a Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Intellectual Property Rights</I></B><B>.</B> The Company owns or possesses licenses or sufficient rights
to use all patents, patent applications, patent rights, inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, trademarks, trademark applications, service marks, service names, trade names and copyrights necessary to enable it
to conduct its business as conducted as of the date hereof and, to its knowledge, as proposed to be conducted as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. As used in this Agreement, the<B><I>
</I></B>&#147;<B>Intellectual Property</B>&#148; means all patents, patent applications, patent rights, inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, trademarks, trademark applications, service marks, service names,
trade names and copyrights necessary to enable the Company to conduct its business as conducted as of the date hereof and, to its knowledge, as proposed to be conducted as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. To the Company&#146;s knowledge, the Company has not infringed the intellectual property rights of third parties and no third party, to the Company&#146;s knowledge, is infringing the Intellectual Property, in each case, which could
reasonably be expected to result in a Material Adverse Effect. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no material options, licenses or agreements relating to the Intellectual
Property, nor is the Company bound by or a party to any material options, licenses or agreements relating to the patents, patent applications, patent rights, inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, trademarks,
trademark applications, service marks, service names, trade names or copyrights of any other person, individual, corporation, limited liability company, partnership, trust or other nongovernmental entity or any governmental agency, court, authority
or other body (whether foreign, federal, state, local or otherwise). There is no material claim or action or proceeding pending or, to the Company&#146;s knowledge, threatened that challenges any of the rights of the Company in or to, or otherwise
with respect to, any Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries
possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement,
the Time of Sale Prospectus or the Prospectus (&#147;<B>Permits</B>&#148;), except where the failure to so possess would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate, authorization or permit that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to have a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Title to Properties</I></B><B>.</B> The Company and its subsidiaries have good and marketable
title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(j) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in
each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or that do not
materially and adversely affect the value of such property and do not materially interfere with the use made or proposed to be made of such property by the Company or such subsidiary. The real property, improvements, equipment and tangible personal
property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property,
improvements, equipment or personal property by the Company or such subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Tax Law Compliance</I></B><B>.</B> The
Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any
related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial
statements referred to in Section&nbsp;1(j) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable
institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or
leased by the Company and its subsidiaries against theft, damage, destruction and acts of vandalism and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to
believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct its business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which
it has applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>Compliance with Environmental Laws</I></B><B>.</B> Except as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of
common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic
substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials
(collectively, &#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements;
(iii)&nbsp;there are no pending or, to the Company&#146;s knowledge, threatened </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental
Law against the Company or any of its subsidiaries; and (iv)&nbsp;to the Company&#146;s knowledge, there are no events or circumstances that might reasonably be expected to form the basis of an order for
<FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B><I>ERISA Compliance</I></B><B>.</B> The Company and its subsidiaries and any &#147;employee benefit
plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its
subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any member of any group of
organizations described in Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company or such
subsidiary is a member. No &#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any
of their ERISA Affiliates. No &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates (other than an employee benefit plan described in Section&nbsp;301(a)(3) of ERISA), if such
&#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects
to incur (i)&nbsp;any liability under Title&nbsp;IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan,&#148; (ii) any liability under Sections&nbsp;412 or 4971 of the Code or (iii)&nbsp;any liability under
Sections 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and
nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>Company
Not an </I></B><B><I>&#147;</I></B><B><I>Investment Company.</I></B><B><I>&#148;</I></B> The Company has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;).
The Company is not, and will not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, an &#147;investment company&#148; within the meaning of the Investment Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B><I>No Price
Stabilization or Manipulation; Compliance with Regulation M</I></B><B>.</B> Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of
the price of the Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;</B><B>Regulation M</B><B>&#148;</B>)) with respect to the Shares, whether to facilitate the sale or resale of
the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B>
<B><I>Related-Party Transactions</I></B><B>.</B> There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time
of Sale Prospectus or the Prospectus that have not been described as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B><I>FINRA Matters</I></B><B>.</B> All of the
information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection
with the offering of the Offered Shares is true, complete, correct and compliant with FINRA&#146;s rules and any letters, filings or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplemental information provided to FINRA pursuant to FINRA Rules or the NASD Conduct Rules of the FINRA Manual is true, complete and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> <B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Eligibility</I></B><B>.</B> At the time the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 was filed with the Commission, or, if later, at the time the Registration Statement originally became effective, the Company met the then applicable requirements
for use, or the staff of the Commission notified the Company that they would not object to the use, of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The Company is eligible to offer and sell securities under the
Registration Statement (including the offer and sale of the Offered Shares) without reliance on General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> The Company has furnished to the
Underwriters a letter agreement in substantially the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;C</U> (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each of the persons listed on <U>Exhibit D</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B><I>Statistical and Market-Related Data</I></B><B>.</B> All statistical, demographic and
<FONT STYLE="white-space:nowrap">market-related</FONT> data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be
reliable and accurate or represent the Company&#146;s good faith estimates that are made on the basis of data derived from such sources. To the extent required, the Company has obtained the written consent to the use of such data from such sources.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> <B><I>No Unlawful Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the
best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the
character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
<B><I>Foreign Corrupt Practices Act</I></B><B>.</B> None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its
subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
&#147;<B>FCPA</B>&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or
other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign
political office, in contravention of the FCPA, or that would result in any violation by such persons of or any applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-bribery or anti-corruption statute or regulation, and the Company and,
to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and any applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-bribery or anti-corruption statutes or regulations and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;<B>Money Laundering Laws</B>&#148;); and no action, suit or
proceeding by or before any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> <B><I>OFAC</I></B><B>.</B> None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director,
officer, agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&#147;<B>Person</B>&#148;) currently the subject or target of any sanctions administered or enforced by the United States
Government, including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;), the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant
sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the
sale of the Offered Shares, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at
the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> <B><I>Brokers</I></B><B>.</B> Except pursuant to this Agreement, there is no broker, finder or other party that is entitled
to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> <B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other &#147;forward-looking statement&#148;
(as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with
reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause
actual results to differ materially from those in such <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement. No such statement was made with the knowledge of an executive officer or director of the Company that is was false or
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B><I>Clinical Data and Regulatory Compliance.</I></B> The studies, tests and preclinical and clinical trials
conducted by or on behalf of the Company and its subsidiaries were and, if still pending, are being conducted in compliance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all
applicable laws and authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder, except where the failure to be in compliance has not resulted and would not reasonably
be expected to result in a Material Adverse Effect; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus are accurate and complete in all material
respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company is not aware of any studies, tests or trials,
the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus when viewed in the context in which such
results are described and the clinical state of development; and the Company and its subsidiaries have not received any notices or correspondence from any applicable governmental authority requiring the termination, suspension or material
modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B><I>Healthcare Laws.</I></B> The Company is and has been in compliance with all applicable healthcare laws, rules and
regulations, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Anti-Inducement Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a(a)(5)),</FONT>
the civil False Claims Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(31 U.S.C. &#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws relating to health care fraud and
abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;) (42 U.S.C. &#167; 1320d et seq.), HIPAA, as
amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167; 17921 et seq.), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C.
&#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the collection and
reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable laws, rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1396r-8),</FONT> any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1395w-3a),</FONT> the Public Health Service Act (42 U.S.C. &#167;
256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs, the regulations promulgated pursuant to such
laws, and any other similar local, state or federal law or regulation, except where failure to be so in compliance would not, individually or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any subsidiary has received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court, arbitrator, governmental or regulatory authority, or third-party alleging that any product, operation or activity
is in violation of any of the laws described above, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened, except as would not reasonably be
expected to result in a Material Adverse Effect. To the Company&#146;s knowledge, neither the Company nor any subsidiary has engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or
permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. The Company is not a party to any corporate integrity agreements, monitoring agreements, deferred prosecution agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any Governmental Entity. Additionally, neither the Company nor any of its officers, directors or employees has been excluded, suspended or debarred from participation in any U.S. federal health care
program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> <B><I>No Contract Terminations.</I></B> Neither the Company nor any of its subsidiaries has sent or received any communication
regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus, the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to,
the Registration Statement, or any document incorporated by reference therein, and no such termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has been threatened by the Company or any of its subsidiaries or, to the Company&#146;s
knowledge, any other party to any such contract or agreement, which threat of termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has not been rescinded as of the date hereof, in each case except as is disclosed in the Registration
Statement or as would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> <B><I>FINRA Filing Exemption.</I></B> To
enable the Underwriters to rely on FINRA Rule 5110(b)(7)(C)(i), (i) the Company was subject to the requirements of Section&nbsp;12 or 15(d) of the Exchange Act and filed all the material required to be filed pursuant to Sections 13, 14 or 15(d) for
a period of at least <FONT STYLE="white-space:nowrap">thirty-six</FONT> calendar months immediately preceding the date of this Agreement; (ii)&nbsp;the Company filed in a timely manner all reports required to be filed pursuant to Section&nbsp;13, 14
or 15(d) of the Exchange Act during the twelve calendar months and any portion of a month immediately preceding the date of this Agreement; (iii)&nbsp;as of the date of this Agreement, the market value of shares of the Company&#146;s common stock
outstanding and held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the Company is at least $150&nbsp;million; and (iv)&nbsp;the Company has an annual trading volume of three million shares or more. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> <B><I>Cybersecurity</I></B>. (1)&nbsp;There has been no security breach or
incident, unauthorized access or disclosure, or other compromise of or relating to the Company or its subsidiaries information technology and computer systems, networks, hardware, software, data and databases (including the data and information of
their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its
subsidiaries), equipment or technology (collectively, &#147;<B>IT Systems and Data</B>&#148;), (2) neither the Company nor its subsidiaries have been notified of, and each of them has no knowledge of any event or condition that would result in, any
security breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data and (3)&nbsp;the Company and its subsidiaries have implemented appropriate controls, policies, procedures, and technological safeguards
to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards. The Company and its
subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the
Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;1. The Company acknowledges that the
Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby
consents to such reliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Purchase, Sale and Delivery of the Offered Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several
Underwriters an aggregate of 6,250,000 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not
jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $37.80 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be purchased by the Underwriters and
payment therefor shall be made at the offices of Latham&nbsp;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, California 92130 (or such other place as may be agreed to by the Company and the Representatives) at 10:00 a.m. New York time, on
September&nbsp;20, 2019, or such other time and date not later than 1:30 p.m. New York time, on October&nbsp;4, 2019 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#147;<B>First
Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the
Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
severally and not jointly, up to an aggregate of 937,500 Optional Shares from the Company at the purchase price of $37.80 per share to be paid by the Underwriters for the Firm Shares, less an
amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part
upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters
are exercising the option and (ii)&nbsp;the time, date and place at which such certificates will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are
simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of certificates for the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to
the First Closing Date, is called an &#147;<B>Option Closing Date</B>&#148; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise. If any
Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same
proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares. The Representatives may cancel the option
at any time prior to its expiration by giving written notice of such cancellation to the Company.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Public
Offering of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Time of Sale Prospectus and the Prospectus, the
Offered Shares as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Payment for the Offered Shares</I></B><B>.</B> (i)&nbsp;Payment for the Offered Shares shall be made at the First Closing
Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
It is understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional
Shares the Underwriters have agreed to purchase. Each of BofAS and J.P. Morgan, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any
Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such
Underwriter from any of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company
shall deliver, or cause to be delivered, to the Representatives for the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount
of the purchase price therefor. The Company shall also deliver, or cause to be delivered, to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First
Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Offered
Shares may be made by credit to the accounts designated by the Representatives through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Offered Shares shall be in
definitive form and registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made
available for inspection on the business day preceding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at
the time and place specified in this Agreement is a further condition to the obligations of the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Additional Covenants </B><B>of the Company</B><B>.</B> The Company further covenants and agrees with
each Underwriter as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Commission Filing Fees</I></B>. The Company agrees to pay the required Commission filing
fees relating to the Offered Shares within the time required by Rule 456(b)(1) under the Securities Act without regard to the proviso therein and otherwise in accordance with the Rules 456(b) and 457(r) under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B><I> </I>The Company shall furnish to you
in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be
delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and
amendments thereto or to the Registration Statement as you may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements.</I></B><I> </I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether
physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed
amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed
under the Exchange Act) without the Representatives&#146; prior written consent. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through
incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such
proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent. The Company shall file with the Commission within the applicable period specified
in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Free Writing
Prospectuses.</I></B><I> </I>The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement
thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written
consent. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when
a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time
through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the
information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances prevailing at such time, not misleading, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided,
however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such
proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an
Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriters that the Underwriters otherwise would not have been
required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Amendments and Supplements to Time of Sale Prospectus</I></B><B><I>.</I></B><I> </I>If the
Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to
amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if,
in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(c) and Section&nbsp;3(d) hereof) promptly prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or
supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or
so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement and until 90 days after
the completion of the distribution of the Offered Shares, the Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission
related to information or disclosures included or incorporated by reference into the Registration Statement; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to
any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the
Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any
order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any
securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the
Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of Rule&nbsp;424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433
were received in a timely manner by the Commission. If, after the date of this Agreement and during any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the
Securities Act or any similar rule), the Company receives notice pursuant to Rule 401(g)(2) under the Securities Act from the Commission or otherwise ceases to be eligible to use the automatic shelf registration form, the Company shall promptly
advise the Representative in writing of such notice or ineligibility and will (i)&nbsp;promptly filed a new registration statement or post-effective amendment on the proper form relating to the Offered Shares, (ii)&nbsp;use its best efforts to cause
such registration statement or post-effective amendment to be declared effective by the Commission as soon as practicable and (iii)&nbsp;promptly notify the Representative in writing of such effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters</I></B><B><I>.</I></B> If any event shall occur
or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the
Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(c) and Section&nbsp;3(d)) hereof to promptly prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146; consent to, nor delivery of, any such amendment or
supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(c) or Section&nbsp;3(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
<B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state
securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in
effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it
is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the
Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company
shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Use of
Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Transfer Agent</I></B><B>.</B> The Company shall maintain, at its expense, a registrar and transfer agent
for the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Earnings Statement</I></B><B>.</B> The Company will make generally
available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after
the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange
Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the
Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a
timely basis with the Commission and the Nasdaq all reports and documents required to be filed under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
<B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on the Nasdaq and to maintain the listing of the Shares on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Company to Provide Copy of the Prospectus in Form That May Be Downloaded from the Internet</I></B><B>.</B> If requested by
the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic Prospectus</B>&#148; to be used by the
Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Time of Sale Prospectus, and any amendment or supplement thereto, that meets each of the
following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered
Shares; (ii)&nbsp;it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be
replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory
to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and
for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it
became effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the period commencing on and including the date
hereof and continuing through and including the 60th<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company will not, without the prior written consent of the Representatives (which consent may be withheld in the sole discretion of the Representatives), directly or indirectly:
(i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any Shares or
Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar
arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the
offering of any Shares or Related Securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(vii) file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares or
except for registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> with respect to any and all Shares or Related Securities to be issued pursuant to any employee benefit or compensation plans, including any proposed amendments
thereto, described in the Prospectus); or (viii)&nbsp;publicly announce the intention to do any of the foregoing. The foregoing shall not apply to (a)&nbsp;the Shares to be sold in this offering, (b)&nbsp;issuances of Shares or Related Securities
pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options outstanding as of the date hereof and described in the Prospectus, (c)&nbsp;issuances of Common Stock or grants of employee stock
options, restricted stock or other incentive compensation pursuant to the terms of any employee benefit or compensation plan, including any proposed amendments thereto, described in the Prospectus, or issuances of Shares or Related Securities
pursuant to the exercise of such options or the vesting of restricted stock or (d)&nbsp;the issuance by the Company of Shares or Related Securities in connection with a licensing arrangement, joint venture, acquisition or business combination or
other collaboration or strategic transaction (including the filing of a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> or other appropriate form with respect thereto); <I>provided that</I>, in the case of clause (d),
recipients of such Shares or Related Securities agree to be bound by the terms of the lockup letter in the form of <U>Exhibit</U><U></U><U>&nbsp;C</U> hereto and the sum of the aggregate number of Shares or Related Securities so issued shall not
exceed 5% of the total outstanding Shares. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible
into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>
<B><I>Future Reports to the Representative</I></B><B><I>s</I></B><B><I>.</I></B><I> </I>During the period of five years hereafter the Company will furnish to BofAS at One Bryant Park, New York, New York 10036, attention of Syndicate Department
(facsimile: (646) <FONT STYLE="white-space:nowrap">855-3073),</FONT> with a copy to ECM Legal (facsimile: (212) <FONT STYLE="white-space:nowrap">230-8730)</FONT> and to J.P. Morgan at 383 Madison Avenue, New York, New York 10179, Attention: Equity
Syndicate Department: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income,
stockholders&#146;<I> </I>equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy
statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the
Company with the Commission or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that
the requirements of this Section&nbsp;3(q) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest, or otherwise use the proceeds received by the Company
from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>No Stabilization or Manipulation; Compliance with Regulation M</I></B><B>.</B> The Company will not take, and will ensure
that no affiliate of the Company will take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to
the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> During the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its security holders that restrict or prohibit, expressly or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such agreements, including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered
into by certain of the Company&#146;s officers pursuant to Section&nbsp;6(j) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>Company to Provide Interim
Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited
interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Payment of
Expenses</B><B>.</B> Except as specifically set forth herein, the Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the offering of the Offered Shares
hereunder, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the
Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public
accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and
certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, and all amendments and supplements thereto, and
this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part
of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a
&#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, in an amount not to exceed $15,000 in the aggregate, (vii)&nbsp;the costs, fees and expenses incurred by the
Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares, including any related filing fees and the
legal fees of, and disbursements by, counsel to the Underwriters, in an amount not to exceed $15,000 in the aggregate, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, including,
without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the
road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road
show, (ix)&nbsp;the fees and expenses associated with the listing the Offered Shares on the Nasdaq, and (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as
provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Covenant of the Underwriters</B><B>.</B> Each
Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared
by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Conditions of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the
several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and
warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the
timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Comfort Letter</I></B><B><I>s</I></B><B>.</B> On the date hereof, the Representatives shall have received from
Ernst&nbsp;&amp; Young LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of
the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited financial
statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B></B><B><I>FINRA</I></B><B></B><B><I>.
</I></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information previously omitted from
the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement
shall be in effect, and no proceedings for such purpose shall have been instituted or, to the Company&#146;s knowledge, threatened by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms
and arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period from and after the
date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as
that term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Opinion of Counsel for the Company</I></B><B>.</B> On each of the First
Closing Date and each Option Closing Date, the Representatives shall have received the opinion and negative assurance letter of Cooley LLP, counsel for the Company, dated as of such date, in the forms attached hereto as <U>Exhibit</U><U>
A</U><U>-1</U> and <U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></U>, respectively, and to such further effect as the Representatives shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Opinion of Intellectual Property Counsel.</I></B><I> </I>On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received the opinion of Jones Day LLP, counsel for the Company with respect to certain intellectual property matters, dated as of such date, in the form attached hereto as <U>Exhibit
<FONT STYLE="white-space:nowrap">B-1</FONT></U> and to such further effect as the Representatives shall reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>
<B><I>Opinion of General Counsel for the Company.</I></B><I> </I>On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Austin D. Kim, General Counsel for the Company with respect to
certain intellectual property matters, dated as of such date, in the form attached hereto as <U>Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></U> and to such further effect as the Representatives shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received the opinion of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On each of the First Closing Date and each
Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in
Section&nbsp;6(b)(ii) and further to the effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and
including such date, there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the
Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied
hereunder at or prior to such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Bring-down Comfort Letter</I></B><B><I>s</I></B><B>.</B> On each of the First
Closing Date and each Option Closing Date, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the
Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than
three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company
shall have furnished to the Representatives an agreement substantially in the form of <U>Exhibit</U><U> C</U> hereto from each of the persons listed on <U>Exhibit D</U> hereto, and each such agreement shall be in full force and effect on each of the
First Closing Date and each Option Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;462(b) Registration
Statement</I></B>. In the event that a Rule&nbsp;462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the
date of this Agreement and shall have become effective automatically upon such filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Additional Documents</I></B>. On
or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them
to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all
proceedings taken by the Company in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the
Representatives and counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required
to be satisfied, this Agreement may be terminated by the Representatives by notice to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing
Date, which termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. The Representatives shall be
reimbursed by the Company, upon demand, for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been actually and reasonably incurred by them in connection with the proposed
purchase and the offering and sale of the Offered Shares, including, but not limited to, reasonable fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges, (a)&nbsp;in the event that this
Agreement is terminated by the Representative pursuant to Section&nbsp;6 (other than clause (g)) or Section&nbsp;12 or (b)&nbsp;in the event that the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because
of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Effectiveness of this Agreement</B>. This Agreement shall become effective upon&nbsp;the execution and
delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any road show, any free writing prospectus that the Company has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged
omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any
Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter
covered by clause (i)&nbsp;or (ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all documented expenses (including the reasonable fees and disbursements of
counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage,
liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement
or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any road show, any such free writing prospectus, or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists
of the information described in Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Indemnification of the Company, Its Directors and Officers</I></B>. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any
loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as
contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale
Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or supplement) or the omission or alleged omission
to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged
untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any such amendment or supplement), in reliance upon
and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all
documented expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or
paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing) are the
statements set forth in the first paragraph under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the heading &#147;Underwriting&#151;Discounts and Commissions,&#148; the first, second and third paragraphs under the heading &#147;Underwriting&#151;Price Stabilization, Short Positions,&#148;
and the paragraphs under the headings &#147;Underwriting&#151;Passive Market Making&#148; and &#147;Underwriting&#151;Electronic Distribution&#148; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement.<B> </B>The indemnity
agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this
Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the
commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a
proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party
and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly
notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided,
however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party
and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the
indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party
under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the
proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are
parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by BofAS and J.P. Morgan (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a) above) or by the
Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a
reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees
and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for
the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any
settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such
indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an
admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B>
<B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses
referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in
such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation
provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand,
and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the
offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of
the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to,
among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand, or the Underwriters, on the other
hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in
Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice shall be required with respect to any action
for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it
would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take
account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;10, no
Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on
<U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall
have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act
and the Exchange Act shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Default of One
or More of the Several Underwriters</B><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on
such date, and the aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the
Representatives may make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be
obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the
Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase
Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the
Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7,
Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for a defaulting
Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by the
Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)(a)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or
limited by the Commission or by the Nasdaq, or (b)&nbsp;trading in securities generally on either the Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, or California authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis
or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic
conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts
for the sale of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood,
earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been
insured. Any termination pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the
Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that
(a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company or its stockholders, or its creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or
will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers, and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made
by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for
the Offered Shares sold hereunder and any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Notices</B>. All
communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Representatives: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One
Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">855-3073</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Syndicate Department </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">383
Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">622-8358</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Equity Syndicate Desk </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">3611 Valley Centre Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: (858) <FONT STYLE="white-space:nowrap">320-8637</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto
may change the address for receipt of communications by giving written notice to the others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16. Recognition of the U.S.
Special Resolution Regimes.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a
U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;16,
a &#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;Covered Entity&#148; means any of the following: (i)&nbsp;a &#147;covered
entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a
&#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street
Reform and Consumer Protection Act and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B>
<B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers,
employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each case their respective successors, and personal representatives, and no other person will have any right or obligation hereunder. The term
&#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B> <B>Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or
provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in accordance
with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby
(&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough
of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such
court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable
law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect
to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding
or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B> <B>General Provisions</B><B>.</B> This Agreement constitutes the entire agreement of the parties to this
Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or
implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows</I>]<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACADIA PHARMACEUTICALS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steve Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Steve Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives
in New York, New York as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOFA SECURITIES, INC.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>J.P. MORGAN SECURITIES LLC</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting as Representatives of
the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters named in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the attached <U>Schedule
A</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>BOFA SECURITIES, INC.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anurag Jindal</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anurag Jindal</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>J.P. MORGAN SECURITIES LLC</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ben Burdette</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Benjamin Burdette</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaccord Genuity LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham&nbsp;&amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>None. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Price per share to the public:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares being sold:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares potentially issuable pursuant to the option to purchase additional
shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>See attached.</I>]<I> </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">____________________, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">as
Representatives of the several Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10036 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">J.P. Morgan Securities LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10179 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ACADIA Pharmaceuticals Inc. (the &#147;</U><B><U>Company</U></B><U>&#148;)</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an owner of
record or beneficially of certain shares of common stock, par value $0.0001 per share, of the Company (&#147;<B>Shares</B>&#148;) or securities convertible into or exchangeable or exercisable for Shares. The Company proposes to carry out a public
offering of Shares (the &#147;<B>Offering</B>&#148;) for which BofA Securities, Inc. (&#147;<B>BofAS</B>&#148;) and J.P. Morgan Securities LLC (&#147;<B>J.P. Morgan</B>&#148;) will act as the representatives of the several underwriters (the
&#147;<B>Underwriters</B>&#148;). The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit the Company by, among other things, raising additional capital for its operations. The undersigned acknowledges
that you and any other underwriter are relying on the representations and agreements of the undersigned contained in this letter agreement in carrying out the Offering and in entering into underwriting arrangements with the Company with respect to
the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, the undersigned hereby agrees that the undersigned will not (and will cause any spouse or immediate
family member of the spouse or the undersigned living in the undersigned&#146;s household not to), without the prior written consent of BofAS and J.P. Morgan (which consent may be withheld in their sole discretion), directly or indirectly, sell,
offer, contract or grant any option to sell (including without limitation any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the
Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), or otherwise dispose of any Shares, or options or warrants to acquire Shares, or other securities exchangeable or exercisable for or convertible into Shares currently
or hereafter owned either of record or beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned (or such spouse or family member), or publicly announce an intention to do any of the
foregoing, for a period commencing on the date hereof and continuing through the close of trading on the date 60 days after the date of the Prospectus (as defined in the Underwriting Agreement relating to the Offering to which the Company is a
party) (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions shall not apply to (1)&nbsp;in the
case of a natural person, the transfer of any or all of the Shares owned by the undersigned, either during his or her lifetime or on death, by gift, will or intestate succession to any immediate family member of the undersigned or to a trust the
beneficiaries of which are exclusively the undersigned and/or a member or members of his or her immediate family, and (2)&nbsp;any transactions with the Company; provided, however, that in the case of any transfer or distribution pursuant to clause
(1)&nbsp;above, it shall be a condition to such transfer or distribution that the donee, beneficiary, </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributee or transferee executes and delivers to BofAS and J.P. Morgan an agreement stating that he, she or it is receiving and holding the Shares subject to the provisions of this letter
agreement, and there shall be no further transfer or distribution of such Shares, except in accordance with this letter agreement. For the purposes of this paragraph, &#147;immediate family&#148; shall mean the spouse, domestic partner, lineal
descendant (including adopted children), father, mother, brother or sister of the transferor. In addition, notwithstanding the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described herein, the undersigned may (A)&nbsp;at any time
after the date hereof, exercise any options or warrants to purchase Shares (including by cashless exercise to the extent permitted by the instruments representing such options or warrants); provided, however, that in any such case the Shares issued
upon exercise shall remain subject to the provisions of this letter agreement, (B)&nbsp;at any time after the date hereof, enter into a trading plan (a &#147;<B>New Plan</B>&#148;) meeting the requirements of Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act relating to the sale of Shares, if then permitted by the Company and applicable law; provided that the Shares subject to such New Plan may not be sold during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; provided further, that the Company is not required to report the establishment of such New Plan in any public report or filing with the Securities and Exchange Commission under the Exchange Act
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and does not otherwise voluntarily effect any such public filing or report regarding such New Plan, or (C)&nbsp;sell Shares pursuant to a currently existing written plan, as existing
as of the date hereof, meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1(c)</FONT> under the Exchange Act, if then permitted by the Company and applicable law; provided that any filing made under the Exchange Act in connection
therewith shall state that such sales were made pursuant to a written plan meeting the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1(c)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer
of Shares or securities convertible into or exchangeable or exercisable for Shares held by the undersigned except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of any Shares owned either
of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood that (i)&nbsp;if the Company
notifies BofAS and J.P. Morgan in writing that it does not intend to proceed with the Offering, (ii)&nbsp;if the Underwriting Agreement relating to the Offering is not executed by October&nbsp;30, 2019, or (iii)&nbsp;if the Underwriting Agreement
(other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of the Shares to be sold thereunder, this letter agreement shall immediately be terminated and the
undersigned shall automatically be released from all of his, her or its obligations under this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and
warrants that the undersigned has full power and authority to enter into this letter agreement. This letter agreement is irrevocable and all authority herein conferred or agreed to be conferred shall survive the death or incapacity of the
undersigned and any obligations of the undersigned shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws
principles thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Remainder of page intentionally left blank</I>]<I> </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Security Holder <I>(Print exact name)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If not signing in an individual capacity:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory <I>(Print)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory <I>(Print)</I></P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Persons&nbsp;Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen R. Davis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin D. Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael J. Yang </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Srdjan R. Stankovic, M.D., M.S.P.H. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elena Ridloff </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julian C. Baker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen R. Biggar, M.D., Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura A. Brege </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Daly </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edmund P. Harrington, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel B. Soland </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d806643dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g806643g0918115426772.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean M. Clayton</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+1 858 550 6034</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">sclayton@cooley.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;17, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3611 Valley Centre Drive, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested our opinion, as counsel to ACADIA Pharmaceuticals Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), with respect to
certain matters in connection with the offering by the Company of up to 7,187,500 shares of the Company&#146;s common stock, par value $0.0001 (the &#147;<B><I>Shares</I></B>&#148;), including up to 937,500 Shares that may be sold pursuant to the
exercise of an option to purchase additional shares, pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-228546)</FONT> (the
&#147;<B><I>Registration Statement</I></B>&#148;), filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), the prospectus included
within the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;), and the prospectus supplement relating to the Shares dated September&nbsp;17, 2019, filed with the Commission pursuant to Rule 424(b) of the Act (together with the
Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement
and the Prospectus, the Company&#146;s certificate of incorporation and bylaws, each as currently in effect, and the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in
our judgment are necessary or appropriate to enable us to render the opinion expressed below. In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the authenticity of all documents
submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents
by all persons other than the Company where due authorization, execution and delivery are a prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not
independently verified such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no
opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Registration
Statement and the Prospectus, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;4401 Eastgate Mall&nbsp;&nbsp;San Diego, CA&nbsp;&nbsp;92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (858) 550-6000&nbsp;&nbsp;f: (858)
550-6420&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g806643g0918115426772.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;17, 2019</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Page Two</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to the filing of
this opinion as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed with the Commission for incorporation by reference into the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is expressed as of the date hereof, and we disclaim any responsibility to advise you of any changes in the facts stated or assumed herein or of
any changes in applicable law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Cooley LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sean M. Clayton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sean M. Clayton</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;4401 Eastgate Mall&nbsp;&nbsp;San Diego, CA&nbsp;&nbsp;92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (858) 550-6000&nbsp;&nbsp;f: (858) 550-6420&nbsp;&nbsp;cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d806643dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO, CA, September</B><B></B><B>&nbsp;17, 2019</B> &#150; ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the
development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other
conditions, $250,000,000 of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering. ACADIA intends to grant the underwriters a <FONT
STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional $37,500,000 of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock described
above are being offered by ACADIA pursuant to a shelf registration statement filed by ACADIA with the Securities and Exchange Commission (SEC) that became automatically effective on November&nbsp;26, 2018. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on the SEC&#146;s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may
be obtained from BofA Merrill Lynch, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NC1-004-03-43,</FONT></FONT></FONT> 200 North College Street,
3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com, or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email to: <FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About ACADIA Pharmaceuticals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA is a
biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for
the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major
depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to
statements related to the proposed offering of common stock by ACADIA. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various factors, including market risks and uncertainties and the satisfaction of customary closing </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions for an offering of securities. For a discussion of these and other factors, please refer to ACADIA&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2018 as well as ACADIA&#146;s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Contact: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Johnson, CFA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">261-2771</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Contact: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maurissa Messier </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">768-6068</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d806643dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Prices Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO, CA, September</B><B></B><B>&nbsp;17, 2019</B> &#150; ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the
development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a
price to the public of $40.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $250&nbsp;million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by
ACADIA. ACADIA has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an aggregate of 937,500 additional shares of common stock. The offering is expected to close on September&nbsp;20, 2019, subject to
customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering. Cowen and
SVB Leerink are acting as <FONT STYLE="white-space:nowrap">co-lead</FONT> managers and Cantor Fitzgerald&nbsp;&amp; Co., Canaccord Genuity, JMP Securities and Needham&nbsp;&amp; Company are acting as
<FONT STYLE="white-space:nowrap">co-managers</FONT> for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock described above are being offered by ACADIA pursuant to
a shelf registration statement filed by ACADIA with the Securities and Exchange Commission (SEC) that became automatically effective on November&nbsp;26, 2018. A preliminary prospectus supplement related to the offering was filed with the SEC and is
available on the SEC&#146;s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from BofA Merrill Lynch, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NC1-004-03-43,</FONT></FONT></FONT> 200 North College Street, 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com, or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866)
<FONT STYLE="white-space:nowrap">803-9204,</FONT> or by email to: <FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About ACADIA Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. ACADIA also has ongoing clinical development
efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press
release that are not strictly historical in nature are forward-looking </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements. These statements include but are not limited to statements related to the expected proceeds and timing of the offering of common stock by ACADIA. These statements are only predictions
based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including market risks and
uncertainties and the satisfaction of customary closing conditions for an offering of securities. For a discussion of these and other factors, please refer to ACADIA&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2018 as well as ACADIA&#146;s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Contact: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Johnson, CFA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">261-2771</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Contact: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maurissa Messier </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">768-6068</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>acad-20190917.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/19/2019 1:02:52 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acad="http://www.acadia-pharm.com/20190917"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20190917"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20190917_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20190917_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>acad-20190917_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/19/2019 1:02:52 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>acad-20190917_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.2 - Release 2019.2 -->
<!-- Creation date: 9/19/2019 1:02:52 AM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20190917.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g806643g0918115426772.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g806643g0918115426772.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V[6M<L- L
M3=W\VQ.BJ.6<^BCN:\YN/BCK%]<-'HVDQ[>P96E?'KA< ?K69J37/CSX@?8D
ME*VL<C1H>R1K]YL>IQ^H%>O:9I5CH]FMK86Z0Q+V4<L?4GJ3[FL+RJ-\KLCW
MI4L+E]./MH<]22O;HD>9P_$[7;"=5U?28_+)Y C>)\>V<C]*]-TS4(=5TRWO
MX XBG0.H<8(^M37-M!>0-!<PQS0N,,DBA@?P-16EK:Z1IJ6\.(K6W4XW-PB]
M>I["KC&47J[HX<5B,-7@G3I\DK]'HT6J*\XU?XIJMV;;0['[7@X\V3.&_P!U
M1SCW./I4>G?%.2.]%OKNF&V4GF2,,"GU4\D?0_A2]M"]KFBR;&N'/R?*ZO\
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M*E1G&?0XQ7!^'_&%_P""E;1=:T^9HHV+1C.'3)YQGAE)R?SJ7Q#X\N?%-O\
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..XJCU?DNA;HHHK8\@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #DB#)/$=6U.>\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/2@,Q$(=?17+?G4TK:L-V+XHG!<&"XBTDTS9T\X=D9+=O;S:V
M6T0?0,@E,[]\\PVD54$H'_$E^H"1#*:KT?8N"176;$\4!$!2>[0RU3GA<G/K
MHY64KW$'0:J#W"$LFN8&+)+4DB1,P"K,1-:U6@D549*/)[Q6,SY\QK[ M +L
MT:*C!+SFP+II8CB.?0L7P 0CC#9]%U#/Q%+]$ULZP$[),9DY-0Q#/2Q++N_
MX?WYZ;6L6QF72#J%^54R@HX!U^P\^6UY_[!Y9-VBX:NJ657\;L-O19//]<?D
M^L/O(FR]-EOSCXW/@ET+O_Y%]P502P,$%     @ Y(@R3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M4LE;HOJ/WW'G,7L&^VWV;M%_"O_.;E[;U>LZ7V975V9 ;'H$/"#8B,AL[5$
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M.U9],]I/C.R&1CL;N_WU/U!+ P04    " #DB#)/G><BOVD"  !/!@  %
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M;SP@,,XA5!LOXI%TIK=WDWL.N]?Z@;%W^^I4TH\:X\<M?P!02P,$%     @
MY(@R3__ )@B]    A0(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<ZV200J#,!  OR)Y0%=MZ:&HIUZ\MOU T-6(FH3LENKOFWI10:$'+PEAP\Q
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M"=MA/7;AWR"I83KOUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%     @
MY(@R3Q\CSP/     $P(   L              ( !     %]R96QS+RYR96QS
M4$L! A0#%     @ Y(@R3R?HAPZ"    L0   !               ( !Z0
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #DB#)/$=6U.>\    K @
M$0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #DB#)/F5R<(Q &  "<)P  $P              @ &W @  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( .2(,D]@S,*=J0(  /D+   8
M      "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #DB#)/G><BOVD"  !/!@  %               @ '7"P  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #DB#)/NJ$YBM<!   R!@  #0
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4!08     "@ * ( "   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627445072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 17, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 17,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3611 Valley Centre Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d806643d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d806643d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20190917_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20190917_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20190917.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20190917",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d806643d8k.htm",
      "contextRef": "duration_2019-09-17_to_2019-09-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d806643d8k.htm",
      "contextRef": "duration_2019-09-17_to_2019-09-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-19-248388-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-248388-xbrl.zip
M4$L#!!0    ( .2(,D\)R<)J8P,  #(,   1    86-A9"TR,#$Y,#DQ-RYX
M<V2]5M]/VSH4?I^T_^$L3W?2$C=%P!I1)G09$A+C3AV;]C:YCMM:<^S,=H#^
M]_?82=JTM%T+TWC!]3G?.=_YZ9Q]>"PDW'-CA5;#*$UZ$7#%="[4=!A5-J:6
M"1%].'_]ZNQ-',/EU?4MQ#!SKK09(0\/#TD^$<IJ63FT8!.F"P)QW.K_>_<5
MOM76,[C(T2R<]).3Y'W21S,C+CFU'/J]=. OEC##J;<'.74\@P%)!\0K09KU
M^MEQ'RX^P4=J'3<*[D3!NU!=SHV8SAS\P]X&RW"IE>)2\CE<"445$U3"EY;Q
M.[A6+($+*6'D819966[N>9XT5A]MGEDVXP5]_0H \Z5LIM!D50PCGX@F#X]C
M(Q-MIB1WAKAYR0DJQ:C%C6!1!_I[W!,,%L)+[ (XH78<0*TDI"?NI?%1VL%1
M1O,59_Y"T+B<45.$6GE8;Y">=D Y%PM,(&<Y2Z;ZGJ!@LQNO)38'U>_UC@@V
MB,.\\PY$"O5S!\*+Q]@:72=/( ]' 9 .!@,2I&N4<K<:1V/]F-3"CK85;'/(
M*/ AIYV0J7-&C"O'K[0I+OF$5A+]5.I71:68")X'+>SL@BNWHK.JX:B9<G=+
M"VY+ROC!9<*VW)0-## EWS_=? D=&YU[ $!H8E&4VCBH>_E&LS!B.XK@?\5M
M[6)_%:=]3$."QB)0&YEO*3R0%Q-I6^)91!;]M#<1NZW[_2%>CL$V#KLFY]G9
M6%\1/A<#GXOT9*]</%DQ?X")5K<O)=/9DX<0VCBI_A O1W:O\JQ-^?-[1%'!
MPBH^K8^>R.D!1);XEW9*9\_YNASO=+^^&!NOP2=52KO@J,N$EJ50$]U<X:4?
ML*R=LA&?0%C(&37,:,EWKVU2&EURXP0^8\M!K0W,#)\,([\/XW8'_I!TG. .
M;%6>.%@=?2\F".'R9DFOQ3KA//C&B\'+\7N RH5IWY[#R&+>96=U_.5P2\,/
M#1<A%E^?4+;M47_N:!T<O/=SAQK@#U]'U[O?K\4#1AQ]U$H7\YKHI6:5?R?;
M_Q<J_ZB0WOP:N\L4@5H$ E^Z$:K_V$M]0;2EFG/\1!6AA=.>_\-/S]9"]TA5
M#K4YZ-@[(^M&UNU7EN?_J?-P9E2R2BX2WX ;C5W ]9+MCUPRVXYK;MNBM:-,
MUF>YN>G.?'U5[QS\^3]02P,$%     @ Y(@R3U4-11>%!@  24<  !4   !A
M8V%D+3(P,3DP.3$W7VQA8BYX;6S-G&]OVS80QM\7Z'>X>6\VH+)C!RL6(VEA
M.,D0+&V"Q-V&#4,A2XQ-3"8-4H[M;S]2?QHYIF0I/%9YT5:5[IZ[1_D=P\AV
M3C]N%A$\$B$I9V>=?O>H X0%/*1L=M992<^7 :4=D+'/0C_BC)QUMD1V/GYX
M^^;T!\^#\\NKS^#!/(Z7<MCKK=?K;OA F>31*E:2LAOP10\\+X\?3[[ 'VFY
M(8Q"50?>#[KON[]V!TKFCD3$EP0&1_T3?>(I31!?ZT'HQV0()[W^24\'07]X
M-!C^,H#1)[CP94P$@PE=D&(J7VX%G<UC^"GX.5&&<\X8B2*RA4O*?!90/X+[
MO.-W<,6"+HRB".YTFE1=22(>2=C-5"/*_AOJOZ:Z5WC[!D#=12:3<V<=?2^R
M6[&9BJC+Q4SU>G3<RU,Z3QF;O93U<9+0/SDYZ257B]&2FF*5>+_WUZ?K^V!.
M%KZG[K[Z:@59&4F',CE_S8/D%M9H$$HC]/^\/,S3I[S^P#ON=S<R['S0!;.[
MXT])=*V.(/$P%#PB%87UY:1Z)XN/MTL53S8Q82')E+]I\R"+F@ORD*IJ]A))
M28+NC#_V0D(30/2!IP^\HW[6YX_JU-<Q5]"/IC(6?A#O5HWTC>(B/YE8.>L8
MDGJ[;>FXD0AVM'P1Y#KJ\,!=R")Z 5=?O67L)8IY^H/@"V,763ENN/@UFD;&
M-C5/ZDC/.&'>E_M#7E.AHC%!)%\)!5F3+W#BYT.B#/_DVO^>]IYJOY96U4(B
MR773?C' O& QC;=W9$9U.19_]A>D+I_FW)8PK33"RV-LH"W70V(W+0!/%4"7
ML";87=]%D)LVCX'S:*%6</4GOHS\65V.GR6U!+"Y=6ZX:(.L00B)U6_*H*6M
M&770:!'.NMWBK;%C54SXT97:86Q^)]MFB^Q><JNK;)D57A%DO\X:!7$7VJP$
M)#5 %4%::IVT;EAK&_2/ ?8Y#U9ZAB;*0UV>=W-:PMC8.-^_9@/MO@X2J[DP
M:&5K0/';+')9LU=,&&^)H#R\8.&Y^MF]*97/DEO&TVR%5P1A &L0Q"8W+0&J
M!N@B:! [:-U(<^W^\;8/5RS@8LE%\E#E/E95QWRE5OOMF(<-?V([(-7JUJ*>
M35X[Q7[;44,>=Q.R4Q"2BI"5!%T3:4_R'7P9=B@O-X<W2I<T(I]7BRD1S>:F
MF-?JD!@,</-U>_R?:^&RKM4AE4?"&KM? \.UFL;#=>)OKD+U78<^T/21^DO8
M+15I%>1#UGB-8'O$*X5Q>5>E8+<6+OU.K1A&X05^\ 9C%(;*ALS^N::,])L-
MA5&@U8&HLL0/!-H/0JDH[A!D^N_R ]"5X(9A[6R<V3 ,P N\N!R @>T #%[=
M  SJ#L# Q0 ,OM\ 3-;<V0 @V:@] )5>T =@K YOQ(2OV8OP+Z:_!O@-=DSH
M/X6A@?]<TA'VN@QP ;H0+O+8!JJ K^<"'?;D9^8;<2OX(V5!PT<_91JO ?LR
M8R;VG\6B#8!1U]$4I \_%$!Y-=Q1<&*E:AX:^$$?BELN8S_ZFRZ;/PTU*[R&
M@3";,HW#3B3:,!A4'8U"6@E4*<PGG.YL5(U!;2\H[RO4-@7QFV"_F]/6NPI-
MC?/]:U;O*=S30<(W^<ZOE7%HQ>]SY_V$-9O%P%&_Z3>ZG7/6\/GZ?EY+6)8:
MX.;K-GB:M9 03<0A4<=ZPNBFWR*J39K&P/5/0>.8L#%?+%8L>WXIZS);DMP2
MN-56>$60#<(5@D@<9Q5@MX0URPX;+P+=M'L,J.]Y1 ,:4S;[I/;C@OI17:)-
MF2WA7&&"ET78@%RFAD3QDSSD^M8(NVJYR&^COC'@O15$SPI1<"1O2M.?QQ$W
M#P_UMQ)5"BW!7,,4/Q1I _<A523(51DHUH&T$"25K'%W;:*(_0N=.!B *RE7
M1-B/@4'G=0Q#N4'S2.S%(PY&B;:K\4C+.9T21XXJ9Z61+90-#PE6:I^U[0^F
M$QI'M9^#[.>UM=DI,\#-UZTV.D8MK&U.)@Y*'1)Y^UV.DWYW]C@-FL; =2)\
M_7'W^^UBRFMOS9\EM02JN75NN&B#J$$(B<],&5)I:S8=-%H$LVZWF&OHQ2:8
M*\^DR<> S;DMKZ5&([P\!F--W=?#7E?S"C@? W;7MW%]K=D\WFN#%PLB9FJ"
M?A-\'<_5)F7ILX:?NRR1:/75P6I;_&"H_>N#%;)(Q&<OJN6%(*T$62FDUP<=
MVC"\0%C72_'$M3K2OP(F.T737X2BSOP/4$L#!!0    ( .2(,D^@(, IS@0
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ML")P&?#A<F6$NJ\+]1XD(3NM9FMWT:E_<*3ADP".N$1L'N@"-YNM2KUUL.
MYS?Q7F\"SVO=U[7#=S[ >@%NL8E=2[U\P",UT@W,,R1FFPD$%=<CXE&5;.!4
MOX<0]GJ4S^"%T#Y@IGLCYGS5>W@T@.48=":&)09B0@;,$W=(:"S$Z;A?8/2V
MM-GZX H$/&2^"S,4"IBD<>2%U&<B4MZ4*! 0-9SJKH?<0R4@!H!&'' P8V;V
M*R+H!V;?GR9E0W"6Q!VV0QN"H[>NR(YBC'QD/I.@\\]\:!N9>$JW6J]BR[6Q
MP!W 0DE<2=']-"WFL<[ADNF>]Q23+PM\D'$4-S19XC',XK:6U3 ?<C-C@W\Y
M#]0*ARQM4QC1R$_9NIK(1XO36Z'%_RUY"!R*\9[(CSU^]6C#=B"$-P!W1X0@
M1(AR^V!O[W#1/-/<]?.[1KV('D\H\PL37#J.$0=,LYB3()-N<!4!\^[5F['D
MS>WQX];^CGU >A^N2+UA5:'B[DH+9"LVWX_8]&'I<X /_)O/L%3 >N']"#(S
MPYJ,8[07!>;>I<7>HQ6[GJR1,]G*)<TDDG5O;_4]JVIZW)TM5ULI_"&D\%(R
M7+@P#UUG$:*E)2^&P\V=D6]1&N^7#:!/Q<D0*)&Y^]:\-438K=1W!KM/*\2F
MSZT8_^!B?*94Q.16F%],F!NLLK?C/*TPQWVN)\S/Z]UG;';C33,)_GBP-*\8
ME5#B8@/BG2=1)-MLNB?)IBM*;YD/3(7S@:D%'IW7;L^Z2;)>K.\:CZ6:=&QG
M1!R/*K5>OD,*^U*=?A]]WB Q)$5Y>MWH:W\ZAIYV%K9)?J!Y.(^3IC5/LG@Q
M>-U9$3X!>09P9JK\<;M\WTM^;KS*3>WZ0.N2C;=CT 0#ZO9#X7PM$UB4R"WU
M(D9^LJIXM)8$> 9W].,EXRZE>*REC)YXT.'[+27SO)O8FP^YS6#!Z$=]E>15
M7(,I=TZ52_\T_$T^4_F5A>33IX6K#AZUD?QX8_7,=]&49V0P)8[>EH(J7T'G
M,9TA.[<EQ!4!6QS< >SEAMQ(<1>.T",(<)N(*N*R(??-\183S;::9/&XVNR4
M6H/L(&,='&HO2(>UDQ9<GXX)\'0,;D:NZ5O4!Y4TU+?>.;D<!.LY&PN#9&"M
M;K!>98UH:]%OUL_<Q^S(SOT.?<'DGA9/E!'E6*"?Q<,VB3;)\!_UZ#TS^,LZ
MUQM,QA/(TG"%=&#N1:&H\86-UQ$($O/ 1P1!\H7V&"/%="V ,=[>Q6MSN-YH
M-7<]()WT6-X4![_C,#0*I0\(0HEDMUQ!.Q!/ZCL82*>.@T=IL#+>B.-2Z2JS
ML>NN=%<;.S1U5[/R5'TRMDJG=./-8-N:79*PO8WB8;=1X-]E-U/HCDK'F>H$
MC &T!Y*:_\A8P ,&/ D6L'='I^H?YF0F7I*46LN.\(3LO&OK?X<IEI,,"N82
M)#W* Z\E>::0[(+!\@W%:&VK,.!:$+@ I1:RL6&25M6R'Q*L7&7:/3!Z>:&-
MDU,\0*ZJ!ASCC+V@_:2#_A?@P!0?&R^3%6>5R0YJ3\S3JUN'O615AB?[<)=H
M):!M*-"]H$5U?/1.FGU0>B.9#L?FNOB2K=)-JJ0]ZL7@%S'L9FRAL@$$%#_Y
MW^IEE7S6QXVRQA(8JV6TZ20+)%/0'\5L3I7H?L5N=<Y/"AZ32IL +A9+!B9@
M(8A0+0&L#'U[5 ,-J.I.*0@JPL05+C^.#@?LE^M-JPRJS?B#*009PNET1\=X
ME HM[BI!&SP 4X E?0?1P,/KO7QCL D,]>NE$G#\:0^]SIG/:9K[8++#BN@P
M!DMCW$L\*!E*,9[K"-K! AV8A1NJ#^+\K@G'W6MO2GZJ-YK5EN$3X$</%E6@
M\!!( H:SBWE3T$MNNEVN]"JM-%&<])24>3:GV)@*]0#N#!*$PE= J8!.M>X;
M3+/ &^S2VH #7G;E@H6MX78\ >:&.81&!R(*YWF\;B4\KJ+!?P%?W2H"PH-\
M3'5[[!<,/5>;**H*S(9YA/JIG(GX ^KC=#Z+N;B<(_L-6DB&Q4B6I5!01&"Z
M9Q,F':XTXF@5-2SBP@I41BC!K@&3!="+ GQL-P[*39CX!#;@YQF/Y?GI14W)
MZZ7DT.8S!26?(7A60H':96!IB71"*48^296&FF.$<G;6TME*> #&U58K&_NS
MTUFSE,%Y.=1#S<]+-N48Y\+C=, ]HV"6ICG%OJ'6/G2L#=YRS.P%PP=4II@B
M/X&%:^SB-$G1\/M]5'($K"<4B123V/BQRSF3W(&: R/>16$!\4;\@+\"H0S_
MJ,@9912VG@E38*Z!< A>0X* 8#]@Q+&X$QQRP'SPI<-Y)#&M,]=M6?<[IE-4
M-QEQ]/B8QYB:RBZP/% E9@!$45*C<>*^7X'%<SI8$S+K=Q3I^,1-TC.LS[-H
MVL+#>GFF_4HC\=QWKK)]]=.^SD7UWFZ,'FPT&I5ZO=7<VX>E++N=:T+& ^9@
M0!OM4+S=%%9_F%\&*#OZ6(2>CC@15Z_0<Y* \YHZ6+,#LD0?D;S-JN-]K8Y;
MAA4H,CYR6!B!7H^"P#-HZ459BYP1AR4\#8L!P,0TJYY.1GP /&A7;3,?7,7I
MWJFLNTPYD@?9%.(U=#J.\F>$AX\R=Z'@(5#)PBFR:'K?8\KPS,!2)5W@W2#-
M218!]^.Q>T+@>;=/GRX7S J/W<!@8=HJM2X0#6US)$:-4?ZQV&=72!J&%!?)
M+%V:0!>D:BA>6'96F9U9C8QX,L,2>#X'R,)P[:.^#T:%HPDTHC ;&',PY@72
MW,TCGS#5&CUH>RO?O K !#PUVA3+]Z2TU51 7$7:;2 O#@Y?ZC&=T6+4O T"
MY$T7J+Z:=*WG3M/Y\7S"-OB$Y/7]P0]I5"M5XXG^-,STJD[BCKL[X^JGR^YX
M]#GVITSO6);+L3PUH[DR<:-=GQ4_X6G*>FGYJOX&-\23A>8U]\ 7#F+-Y1&4
MCLUYO!C(@@E=E](+H,>2$'/=.I<C;K!1>7\"Q<NRR)QN68]!\@:O[LUE3GR)
M3$=;>QA!QINM4CLM?U'>,@E;<DU$_C*'UEI7/KR%6D^7JW$_5^2WP._EAXU6
MND<P:QZL.<[;C(4WV87/;@NA(_%P-9%!X'E4PHMD.N0V?:N6Q<:K-WY-E8W)
M3HXH,3?^NRUK?W^OX;*);5='X;ATO"S0YNHHXA+/ N:,;I7&5FF\N-)H;I7&
M:RJ-9JPT+@HC+5NEL%4*+Z44ZHVM)G@+FJ G?*6#[CE-L&,V>DP\-Q,AW=WJ
MB*V.>#$=H8/&6QWQ:CJBW8Z5Q*6.\E^9*/_6M=AJB#>D(>I;#?&:&J*^U1!;
M#?&&-81M[6WUPXOHAYX <,DEL#4YPZTI:C)C3FA(B;Z*?0=U@8M.!6;(Q&D9
M9_KMP01?'TS<^-50NPNZ8<-=WL?N2A>D&GP0\HY*M_))B*\8:<WL3;]0MHC>
M?NX!1U">R992:0YLG,RC4S@P#P-/F\#OH9#(0F0(\V$2-(8Q*EZ,2J8OD__A
MWPH/9H[&-XWJ5Q]Q]=7LPD>^8V P:69]S.=9T6/L2&9_FD_H25),DY0C/ U#
MS;V#^GC1./#T<A)GNRW)0DJ2F-*DW342?K.9+=<ZGR4#)I)*IP(&DL7OE5 $
M7VSK8M:6$TFIDY_\]'W7&@0S?)*KA\G/FU"SZX017K>KD^'-41\5>:'2.8$N
M1V#3V[.\% V1 *[==<1/9UEE<'$CG7QU2R47D=*\(/+YG#E S!3%%T_JFR9I
M\EZ-E:G!9:*$.?5MDN:0A)CU'"DUR[]4+)Y;JG<PH2#.*K\"JI /!K0XJSQI
M,Y\Y2'T?Z12S_-H)@[8UNU\SR<W$-\81<P[KA#D9<Z5AFTP\S&.Z8YZ'GT6P
MJ&B@V)\1,H-) %2;9 !6R7]$I GET"BF1WQ.#-C>89A8&V&^J\=-"KT?9UXM
ME[ER3'T5@'%A6)BF.7QHF>G\*S%$GL?#CF9<S(O369NS3%Y%AU"7R@'FPLYN
M"8U[NI3\%CO+GC* C_@*TBL\+S2>90"WF\#=0,05J@*)D$LDA%&XS*42AAF
MD05G2:.)^"<2KK$(Z5> RA?9NU&!L.;\'(I7%&AZY/0GE@_QQ%Y&#!TN86DR
M+YM7<9;_ C73HVKK'+G2AZ"2EZT1_4;XMW[XZO4.?_?//IYWK[]<G?9?-C7S
M<BZ!68*< R\:=EWO1'*YZ$"H&X%, ALKG5^9XSU,_ :(S2*#.68#-J+>,%G\
M-%O'%4P.,+31W<$DC6"I_XNYU6\P+RU3ON:M0WNK<\Y67R6T_HU%\S4W&F7O
MD7EOSWB_R"/S-,TK83L++GXK=?&+?:[7\'\>C>HCD7F5US\\#--5QQR?(&#S
MW&\?>M/5OCL-L)7QMXK,+]/.F]; >0Q0812CN"QK>3*?M5Q3-=(%QQ2<AI,J
M^8V/[]%66\';(O,<R.#E4V];]#8W";9B]2U.VW>%C+Z4\#N3J]/TE6K_PGLM
M< .5NSIS.WD!#[X=73$O29^U&JU#C#9(%F+H:\4>R0-#4$>U@7"G4#0*Q][Q
M_P-02P,$%     @ Y(@R3Z1H@B$4I0  '4(# !    !D.# V-C0S9&5X,3$N
M:'1M[+UK<]S&DB;\G1'\#PCOS"P9 ?*0HJZ6CR.HBVWNR))6DL^9>;^AN]$D
M+#30!KI)]?SZS6M5%E#H;E*4:+W'&[/'(MD-U"4K*R]//OG#+Q]^??7C#[^\
M/'WQX^[.#Q_./KQZ^>/+_SHX/CS^X6_\$_SZ;_+WY(=G;U[\=_+LY^=O7KUY
M]_?O_OG+V8>7W^$?DMT=^-SSO%KDS8\_O#C[1_+^PW^_>OGW[ZZ*R>+B^\>'
M#XKJNR0KB_/J[]^5^71!W_KAK7YLEC7G176PJ.??'\T73Q/Y>50O%O6,?S6M
MJ\5!6_Q/_OVQ_WF:S8IR]?V'8I:WR>O\*GE7SS)XT^FKLY]?__V[ICB_@%?]
M\ SF],O9L[,/"4PL^>%OSW[\X6]O<6:Q 3S\(@.@EY[!?\[HI[,?7W[*Q\M%
M45?)/_*FA?_2GX)/;1KI\;U;'.J8-H_&^C"]]^ H/3HZ2MY?9 U\6L<1W[';
M7# SBM/GIR_.3G=WWOYR^N[7T^<O?_MP]OSTU?OD[/7SP[L9T0^__?C;ZQ<O
MW_WSW=F'L]<_)Z<_OWOY\M>7KS_ <'[[\6MNELC5^WR^R&>CO/F/:M3.GQX_
M2I-[1\=/DN&5N951_/BLGIXF[T%^FV)1Y&V:G%7C0U040Z^]C4/]X_\Y?'N8
M_%HWYUEE7IZ\>O5\S82'WKS(/RT.BFH"N_O]_7^_YDBR=G?G73Z'HP%?SQ;%
M)?RYGB:+BSQI\\N\R<KD-WAT<P5#A,/='9YY%VY'9[2]P7[W(V\O/06U].FS
M5R_U6<_>O .)/ "-_.KT[?N7W^L_ULZ@.]WO$G[,W[\[^BYY_O+5J[>G+UZ
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MGCQ%%\ F+]#U+*8%N3MP,9J U3,;L%*Y@"&,\6G6AO;KUPEY/3=/Z._8#[Q
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MU.$'TV]W!V,"Z;8;M?U.#"SU[9P+O])T#"8<^[K.DK-._[PU;R+1G2L?W0F
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M,EEV#B%MD>2$I"27.$E!UP;;@;>WN,)FKKR;O:V2:=-,<6K/\?%U4Q69"TK
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MF)]R..7XR:/[7+@Y(WH^TUS3&!KD92ZU>4-HSDF8C-\^>&/BHIA+<C_H!D&
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M0@BR.4*!6&"OF,Y1C6J,E"JQA<AI7E,1$4S=/(["!-("$J\U&!K!:CR#N!1
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M $!8V+<5#(-@$&),TTQGDHQT]7E-=7U61T)8F=1C:PKMKG:L";4#N7/.U3
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M-LQK?M@S>QLSM+&E6O("&EPHW^KQ\J29-W3LQ46@ ?*.$ F D0> "UR=$#=
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M+A[RQF;K\^V40WPW.FUK9VMW?VMYZ1!@"\P)F6!RJWB8^WI]H]L-?H-NS:L
M!"DW&Y.#K7OO&N5X M6"ZZNK][X&Q^9RV8VCLZP=[&P%;]:ZZZO<]_% "G7S
MU>8<"G5];?7%YL;ZZ\=@+7SDO/H.(V%=PX=9[-6V?HW< &!2LEEN##3V^Q!2
MPH(>!6I:<EB,KWI&",,EL&()JH!G7CRD2\9.V$;'>!B]["R-=2S\:^>XL[QT
M#,6M9NV/(N-O4IT_E(.91[+G=L]]=( PN4\A:RIU(QR><DH'(VP0+-YAWM4]
MZD<DVK5"=P:'&I:'?>GE)9A]T#AYKA*#H)Z-UE7Y2\O>=]LZZ1+THUB+"X%2
M0*6NKJKM$+AMTHCE"'LR.$XFH PR,FH6];[E^!?T'*$HOC1)ZO6LGP"#R-3.
MHDT-H6>P\JFK#DK";S;X5*D1";E_O^[W#U >","B-Y RG-#V+SO80;,ED>+:
M&KH9 BD(P6$P2R"EJ>6(FG/J9(@&+,67WR&A!%%] 5VLC V*A1T"#94QNZ]A
M<WEPAFV_N<)[Y^KFTGAZ5A#M VX@B'<B87=YI<S1/;<!@5TN.JW(#M><GO/Y
MEDXNX$>AGK&L7+<:EK[* /TZ>&8^/3+W&Z<L?"R\=M!=PWW9Z< #-UZ_"[J;
M+[NMBY4.O\"7>7X+#*S0I844/C-C?:MH%?D)S(D-F1/UB%!Z3F N,90V#9@^
ML<UH<C/'O=/YT#FRXUY[M=;97#-'^AWS;/NOQW*]NWKWR]>==7RSC^9K+AA_
M#!^.]^]J".N;:QV8O>R;=S#GDBL[FFN($(T%IVL&HW>DVX;568.5@2%V"73,
M5K_+<*?K/4_L!)'8 R__P!RINQ&V#!FU7DQR'.-6S]6P.Y[4 HDB)LF9H\=T
M 797[7D"'>/!_K[(^6[6[[_X8!Y\$?P.JW-LG)UH#,H,L%T"(F=*(1><0_'=
MF'/JBXWAT87O7SOPON,)XMEDI5[)DYI<4)PR<B'62A%:EF0]C%2=Q@21@%RL
MU:!\N87.5=@'\Y4)&9]48'*9 :$T#C3Q;7ZWK4F/;9;,*"TI$F#F>:G[*">,
M9F"8UY4+R4G7S)GE!'1AUYL^32]#7$LO62!]Y%X?(NT#M8A""0M1?>;:%%5"
M=\(WBR@ML]N%M]M>1X0/:'EE2W>:^C6EF=J"+=3U?YEC _4?5:1G>?KCRP5O
MVM36(<@O9E&YRI9K[BC7!:L;IY=A$O?9=IR4/B=9SB+BJAG'_H>\D%*,5O4X
MU):$A"<+*ZO?5?\F3AK7O<_5OO$I0I3.QN$%TT:G@#J?:L!V??5'"M@N6%S,
M9U5A"PFZ((I@2=83<JOS"JB7!IW"0V^>!7T(U(,1M*@:/KFJ^27RNV+38X7<
MVNAZ&@56(;A!/#Y-\L9JDH_H\<#=\BG\!G8$5Z%.NW+M8FIWB:^J J#W2K8;
MP;RCHN!6B<3SK([%C;)9(M6R".ZK+4YA%KQ4-M#</6 ,*81.=,FHCIG U@ I
MN:U T#1B<LY4N):U75&V5P%8;1A$JJYJ2Y=:]D8[XC+.0_M&=;6MB-<,CC)W
M\PD?*]N7QL'-QTWNYR#8,C>862,D<E'?WLZ0[PT^<1"FQM(>(\HPY1!8(=MU
MYEGY;ZINAV<WU+\/T#GG>&&K9RP9LC<2IH:SZW5LN]YW<#QJL31,"<'@&>OG
M,NL1"]KD=!B/57V7L120Y///B=G@?MQCL#$JYAMX,E"4UI]JAASX.9YAAR&I
MZ_HE: 5E)6:X1FD$E:W_E3_O3Z4H]81[XS12-U<7OYWFB@34;4,"[::F<&L^
M!,83BO)+KDFV- T%$H\/AUC^)8!_KO\6SCM4Q!!+O 4GE&X_"6:[LJX2LJ(+
M'1;NY5)8:ADD2F.V@ ER?(784$\4Y\X0AVSC:U$!*?(PVZ'E(HS9:,TP8*8*
M1Q/BQS:#H_PY+1%@G,P8&HM_6:+)")]S/%R\3K7(63""@EN+XEB=M LHUN[X
M_*OG*J6]CT"3B!FH68B8:\@FP_L'O?N]!K^QJF?;3:H"U[:P;>A0. C19@XU
M-F!C+R\A.#;(;HSI&//0ENVMH9TV%T>,"K3 \(LQB,@8MDCP*^2-Z*/>KI%^
M\QJC/WOGC%H,5(L,78P"@7 *HH2H"CKZ'O4F(K2.+Y7\+WF[ATG7()RD8W6M
M+AYOO<*BSKSUI355,7Q9HZ9#X%7 D\A1JFL4X3;X:T2#DO[S4,@8\!!@ZRCC
M=H U $<DZM<,)1PS]$JI%QT_594?;$JM3MI&"=JJVTD 8 G@U;[1KUXM7]\?
M,I21X%BD)=BG+UH\L4'0??-Z@R)80VQ$?G16Y-JJLR(YGUJR'QU5E6=+H9F(
M=V[!U^PXSB-GYMG>&4=N1QS,[A'$5@NAAPBI.)*D1(<"9R^73EEF-C"VFOE9
M&F78HPJ_5%7/S M(A;2DJ=/HS%Q]'#^K*V(OD72(]WI2VY)/!Y7/W[?,@M-@
M\7J4PV0+071+N8,B!O/"$9S!M.(S8,UJ*PA[3-8QMTLA<*H0;0W'DUQZ*O$D
M]Z4*%9,=-AJ&3XC1=*>2WIH),#HLRR(-OD_'FNE35.DLJ$\@X?6W48)M'#VR
MMYX4-[>XKP)#$/$0X;2MF8Q:QKZ+_^6_4NND<V9<<"^!]NF(#R1'YLA.X""#
MXX[GX8"/-[ &,E]\KG=+9H5NHL\)K0(C[!'9:]C&MYO*J:=5<MS-E;K',>ZZ
M8F7=3B=P<)B>++*1&?<X)E? =J>64$V--OYK8CZ17+D8(MVN0D'6G^2H;[VC
M1D9X#::M!%EG*&)R-&L(7J;U5]JZ>HMRW/P-&T\MT(2X8KSUJ*^&CBQB[AF=
MH&:=EY=XH0?F$D10^\J"EU:@=NST5_YYT%V5%M5!&.?)E: @"WA0<8%G-2$+
M@6/3+EA74KRN92+RFSS XS*";E[!9JWYMY4#!PE$3+DYHTV+0"PO06]CDN%O
MK+V)SCU;#<UPE<C9#MN=0NQEI'@1X'L-* 6L6 =@4(O*<%^U J! #%I2F( J
M;VC#\0CTS]$(,2.%[X^<NS*G'AI!MAC8W&(J0Z.1,>\\9UR.-/X#&"7WW_\/
M$$W*=4&L$]RB +_]7_/;@,@GGV@\M?LCQ5-O=!7L#WQY!@570VIW96QVWU["
M\)GY8>CJ>B[,(" X \:M^1"$;HU\57HRR?X#50!P8=!'X]3\-\P8V6"<LU#
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MO4LM$*)U J$+BD-:6=XL+1RD-H'W\6KKMP)R7\C<6(0YED2([.IAAJ$H"F^
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MC>%.C/%<%C3;U#!8C[7=>)2QB&1'M,+(1F=$,LOI4]9S$ZH<?] L?&20R_?
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MG57*U=*;VWS ;8D5[MKL"FH[8B;<QB%-3UZ#ZU<O8H_\2;! _#<2*A0V\Z*
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M=W\?YC1; >LYI]HTZU<!/A,9-XYR$;!!BFBV63QM;#+PNQ$?<V&=_3GD:=)
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MU[QLLC-MQIRLB L*.3:>GO9\(O&0#H@21>>3EJC3H=8W#5,H16]P-A]3L)!
M?DWEJR: ;H9R@9!Z[>K#$3L5]/SFUK$_C'"L&ZG@217BA3Q2OH?$@=@3Z;[B
M&4^3X/XG/,M?0GPSHA4\CE'I[(U0A73SB+T[NURUE,XY1U5->+:^.P#6FK9
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M2C::N/C=^78WU>UNTM]I\=#_>?<O4$L! A0#%     @ Y(@R3PG)PFIC P
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M,V0X:RYH=&U02P$"% ,4    " #DB#)/I&B"(12E   =0@, $
M    @ %E)   9#@P-C8T,V1E>#$Q+FAT;5!+ 0(4 Q0    ( .2(,D\CC8J.
M.PD  (@C   0              "  :?)  !D.# V-C0S9&5X-3$N:'1M4$L!
M A0#%     @ Y(@R3WI$9%.C"0  $!P  !$              ( !$-,  &0X
M,#8V-#-D97@Y.3$N:'1M4$L! A0#%     @ Y(@R3VP1MVY8"@  Y1T  !$
M             ( !XMP  &0X,#8V-#-D97@Y.3(N:'1M4$L%!@     (  @
*^P$  &GG      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d806643d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20190917.xsd" xlink:type="simple"/>
    <context id="duration_2019-09-17_to_2019-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2019-09-17</startDate>
            <endDate>2019-09-17</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2019-09-17_to_2019-09-17"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2019-09-17_to_2019-09-17">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2019-09-17_to_2019-09-17"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2019-09-17_to_2019-09-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2019-09-17_to_2019-09-17">2019-09-17</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2019-09-17_to_2019-09-17">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2019-09-17_to_2019-09-17">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2019-09-17_to_2019-09-17">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2019-09-17_to_2019-09-17">3611 Valley Centre Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2019-09-17_to_2019-09-17">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2019-09-17_to_2019-09-17">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2019-09-17_to_2019-09-17">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2019-09-17_to_2019-09-17">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2019-09-17_to_2019-09-17">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2019-09-17_to_2019-09-17">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2019-09-17_to_2019-09-17">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2019-09-17_to_2019-09-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2019-09-17_to_2019-09-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2019-09-17_to_2019-09-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2019-09-17_to_2019-09-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-09-17_to_2019-09-17">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-09-17_to_2019-09-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2019-09-17_to_2019-09-17">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d806643d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20190917/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d806643d8k.htm">d806643d8k.htm</File>
    <File>acad-20190917.xsd</File>
    <File>acad-20190917_lab.xml</File>
    <File>acad-20190917_pre.xml</File>
    <File>d806643dex11.htm</File>
    <File>d806643dex51.htm</File>
    <File>d806643dex991.htm</File>
    <File>d806643dex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
